FURIN and ovarian cancer: The specific Furin inhibition using a bifunctional GM-CSF-Furin shRNA construct and an in vitro transduction protocol on the patient’s cancer cells have been efficacious and well-tolerated in phase I-II trials with advanced Ewing’s sarcoma [19] and ovarian cancer patients [20].